Celltrion Pharm Q3 Sales Reach 128.1 Billion KRW
Record-Breaking Quarterly Performance Achieved
Celltrion Pharm's third-quarter sales reached 128.1 billion KRW, marking a 37.2% increase compared to the same period last year and setting a record for the highest quarterly performance.
Operating profit for the third quarter rose by 108.3% during the same period to approximately 13.6 billion KRW, with an operating profit margin of 10.7%. Cumulative sales for the third quarter totaled 342.3 billion KRW, and operating profit amounted to 26.8 billion KRW.
On the 15th, Celltrion Pharm explained that sales growth was driven by strong performance of key products and the effects of new products, and despite increased staffing and research and development expenses, they focused on improving operating profit through reductions in sales commissions.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- NVIDIA Reports $81.6 Billion in Q1 Revenue, Surpassing Expectations
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Celltrion Pharm plans to accelerate growth by expanding sales through market stabilization of new products and increased production volume, while aiming to become one of the top five domestic pharmaceutical companies by 2030 through investments in research and development (R&D).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
